FDC Limited announced its unaudited consolidated financial results for the third quarter and nine months ended December 31, 2025. The company reported revenue from operations of ₹465 crore for Q3 FY26, a marginal year-on-year growth of 0.1%. This performance was primarily impacted by lower sales in the Domestic Formulations business. Despite the overall flat revenue, the Export Formulations business demonstrated strong growth, increasing by 55.0% year-on-year to ₹71 crore in Q3 FY26, contributing 15% to the consolidated sales. The API business, however, saw a decline of 17.0% year-on-year, with sales of ₹23 crore. For the nine-month period of FY26 (9M FY26), revenue from operations stood at ₹1,586 crore, a decrease of 1.9% compared to the same period last year. The company's EBITDA for Q3 FY26 was ₹52 crore, with margins improving to 11.2% from 10.1% in the previous year, driven by higher gross margins and enhanced operational efficiencies. The Domestic Formulations business reported sales of ₹369 crore in Q3 FY26, a year-on-year decline of 5.2%. For 9M FY26, this segment contributed ₹1,329 crore, a 2.5% decrease, attributed to lower sales of key brands like Zifi, Electral, and Enerzal. However, secondary sales data indicated a 4.8% growth in the domestic market. In the US market, revenue from supplies showed a significant year-on-year growth of 82.8% to ₹43 crore in 9M FY26. Overall US business revenue grew 2.1% year-on-year, although impacted by a lower profit share due to a recall. The company received US FDA approval for Pilocarpine Ophthalmic Solution during the quarter, strengthening its ophthalmic portfolio. Profit Before Tax (PBT) after exceptional items stood at ₹36 crore for Q3 FY26, a decrease of 28.9% year-on-year. Profit After Tax (PAT) was ₹28 crore, down 23.6% year-on-year. Consequently, Earnings Per Share (EPS) for the quarter was ₹1.74, compared to ₹2.28 in the prior year.